Avacta says salivary gland cancer drug shrinks tumour
(Alliance News) - Avacta Group PLC on Wednesday said new data demonstrated that its drug caused "robust and meaningful" tumour shrinkage in patients with salivary gland cancer. Read More
| Price | 56.00p on 15-01-2026 at 18:50:04 |
|---|---|
| Change | -0.40p -0.7% |
| Buy | 57.00p |
| Sell | 55.00p |
| Last Trade: | Unknown 35,000.00 at 56.60p |
| Day's Volume: | 1,450,842 |
| Last Close: | 56.60p |
| Open: | 57.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 56.60p - 58.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £245.45m |
| VWAP: | 57.18912p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 35,000 | 56.60p | OTC Trade |
17:07:28 - 15-Jan-26 |
| Buy* | 36,000 | 56.60p | Suspected BUY Trade |
16:35:13 - 15-Jan-26 |
| Buy* | 892 | 56.1028p | Ordinary |
16:22:12 - 15-Jan-26 |
| Buy* | 3,511 | 56.96p | Ordinary |
16:21:14 - 15-Jan-26 |
| Buy* | 10,980 | 56.10p | Ordinary |
16:21:05 - 15-Jan-26 |
| Sell* | 3,390 | 55.75p | Ordinary |
16:20:06 - 15-Jan-26 |
| Buy* | 35,000 | 57.25p | Suspected BUY Trade |
16:14:28 - 15-Jan-26 |
| Sell* | 55,000 | 55.625p | Ordinary |
16:11:53 - 15-Jan-26 |
| Buy* | 18 | 57.00p | Ordinary |
16:06:11 - 15-Jan-26 |
| Buy* | 1,754 | 56.8972p | Ordinary |
15:47:34 - 15-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |